BioSpace News Archive

Elicio Therapeutics, a next generation immuno-oncology company, announced today that Christopher Haqq M.D., Ph.D. has joined Elicio as Executive Vice President, Head of Research and Development, and Chief Medical Officer.

Cleveland Diagnostics, Inc., a clinical-stage company focused on developing next-generation diagnostic tests for the detection of cancers, today announced that its chief medical officer, Mark Stovsky, MD, participated in an Impact Session at the 2019 Medical Innovation Summit organized by Cleveland Clinic.

The Multiple Sclerosis Association of America (MSAA), in partnership with Novartis Pharmaceuticals Corporation and Emmy Award-winning television personality and multiple sclerosis (MS) advocate Montel Williams, announced today the launch of My MS Second Act

Results follow recent updates to ProMIS antibody programs selectively targeting root cause of multiple neurodegenerative diseases

BrainStorm Cell Therapeutics Inc. will be participating and presenting scientific data at the upcoming Neuromuscular Drug Development Summit, from October 23-25th, in Boston MA. The Summit is dedicated to solving the challenges in developing second generation neuromuscular therapeutics..

On 31 October, at 08:00 CET, Swedish Orphan Biovitrum AB will publish its report for the third quarter 2019.

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced it has entered into a strategic collaboration and license agreement with Novartis covering the development and commercialization of Pliant’s preclinical product candidate, PLN-1474 and up to three additional integrin targets.

Cedilla Therapeutics, a preclinical biotech company harnessing protein stability to create the next generation of targeted cancer therapies, today announced the appointment of Justin Birtz as vice president, people and culture.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2019 on Thursday, October 31, 2019,

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced three oral presentations at the American Society for Dermatologic Surgery (ASDS) 2019 Annual Meeting to be held in Chicago, October 24-27, 2019.